Βk-2C-I

From WikiMD's Wellness Encyclopedia


Βk-2C-I is a synthetic psychedelic compound that belongs to the phenethylamine class of drugs. It is structurally related to the well-known psychedelic 2C-I, with the addition of a beta-ketone group. This modification places Βk-2C-I in the category of beta-ketone phenethylamines, which are sometimes referred to as "bk-2C" compounds.

Chemical Structure and Properties[edit | edit source]

Βk-2C-I, or beta-keto 2C-I, is chemically known as 2-(4-iodo-2,5-dimethoxyphenyl)-2-(methylamino)propan-1-one. The presence of the beta-ketone group distinguishes it from its parent compound, 2C-I, which is 2,5-dimethoxy-4-iodophenethylamine. The addition of the ketone group is thought to affect the compound's pharmacokinetics and pharmacodynamics.

Molecular Formula: C11H14INO3

Molecular Weight: 335.14 g/mol

Pharmacology[edit | edit source]

Βk-2C-I is believed to act as a serotonin receptor agonist, similar to other phenethylamine psychedelics. It likely exerts its effects primarily through the 5-HT2A receptor, which is known to play a significant role in the psychedelic experience. However, detailed studies on its receptor binding profile and pharmacological effects are limited.

Effects[edit | edit source]

The effects of Βk-2C-I are reported to be similar to those of 2C-I, including altered sensory perception, visual hallucinations, and changes in thought processes. Users have described experiences of enhanced colors, patterns, and a sense of euphoria. The onset of effects typically occurs within 30 to 60 minutes after ingestion, with a duration of action lasting 4 to 8 hours.

Safety and Toxicity[edit | edit source]

As with many research chemicals, the safety profile of Βk-2C-I is not well-established. There is limited data on its toxicity, potential for abuse, and long-term health effects. Users should exercise caution and be aware of the potential risks associated with its use.

Legal Status[edit | edit source]

The legal status of Βk-2C-I varies by country. In some jurisdictions, it may be classified as a controlled substance, while in others it may be unscheduled. It is important for individuals to be aware of the legal implications of possessing or using Βk-2C-I in their region.

History and Research[edit | edit source]

Βk-2C-I is a relatively new compound in the realm of synthetic psychedelics. It emerged in the early 21st century as part of the wave of novel psychoactive substances (NPS) that have been synthesized and distributed, often via online markets. Research on Βk-2C-I is limited, and much of the available information comes from anecdotal reports and user experiences.

Also see[edit | edit source]



WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD